Epicardial fat is considered as indicator of cardiovascular risk. Several studies have tested the association between epicardial fat thickness (EFT) and coronary artery disease. The aim of our study is to test the hypothesis that echocardiographic EFT is a marker of coronary artery disease. One hundred and ten patients (70 males and 40 females with mean age of 51.5±10.6 and 52.6±9.6, respectively) admitted for coronary angiogram underwent assessment of epicardial fat thickness by echocardiography. Routine clinical examination, evaluation of risk factor profile, and anthropometric variables were also done. Epicardial fat thickness was measured on the free wall of right ventricle in parasternal long- and short-axis views at end-systole for 3 cardiac cycles. Mean epicardial fat thickness in angiographically normal patients and acute coronary syndromes were 4.4±1.2 and 6.9±1.9, respectively. Epicardial fat thickness in males and females were not statistically different. Burden of coronary arterial lesions denoted by Gensini score shows linear association with epicardial fat thickness and the severity of the coronary disease. Epicardial fat is independently and linearly associated with CAD and its severity.
Carotid artery dissection (CAD) is a frequent cause of stroke, accounting for up to 25% of all ischemic strokes in young and middle-aged patients.1,2 It may be traumatic or spontaneous, with multi-factorial etiology. A tear in the arterial wall causes intrusion of blood within its layers, producing intra-luminal stenosis, or aneurysmal dilatation.3 Thrombo-embolism arising from this anatomic disruption has been postulated as the essential stroke mechanism in CAD.4 Bilateral internal carotid artery dissection (ICAD) has been rarely reported.1,4 Antiplatelets and anticoagulation remain standard therapy for CAD.5 However, in patients with either expanding pseudoaneurysms, severe flow compromise, worsening symptoms despite anticoagulation or contraindication to anticoagulation, endovascular stenting is beneficial.6 We describe a patient with ischemic stroke from spontaneous bilateral ICAD with completely occluded left ICA. Having failed medical therapy with antiplatelets and anticoagulants due to extensive loss of carotid vascular supply, he was managed successfully with endovascular stenting with good neurological recovery.
Background/Objectives: Severe coronary calcification complicates percutaneous coronary intervention (PCI), and several calcium-modification technologies are available, but direct randomized comparisons are limited. We reviewed the comparative evidence on procedural success, complications and clinical outcomes. Methods: Comparative studies of coronary calcium-modification techniques during PCI that reported procedural, safety or clinical outcomes were eligible. PubMed and ClinicalTrials.gov were searched in May 2025 for records published from 1 April 2015 to 1 April 2025 (PROSPERO CRD420251077471; no external funding). We included 32 publications: eight randomized trials (10 publications) and 22 observational or descriptive studies. Evidence was organized in tiers and synthesized descriptively, without pooling, because definitions were heterogeneous and event rates were low. Risk of bias in randomized trials was assessed with RoB 2 where full texts were accessible. Results: Procedural success was generally high (usually 85–100%) and major complications were uncommon, but success definitions differed, and reported dissection (0% to over 80%) and slow-flow (0% to 31.6%) rates varied widely. Most comparative data were observational. In randomized comparisons, no device consistently outperformed another for procedural success, stent expansion or minimal stent area. Clinical outcome comparisons were limited by heterogeneous endpoints and low event rates. Risk of bias was rated from full texts for five out of the eight randomized trials, none at low risk overall; ratings for the others were provisional or not possible. Conclusions: The evidence is largely observational and of low certainty, and is insufficient to establish clinically meaningful differences among most technologies. Device selection should be lesion-specific and imaging-informed, and adequately powered head-to-head trials with standardized endpoints are needed.